Results 31 to 40 of about 5,871,156 (346)
European Journal of Surgical Oncology, 2023 The need for a common education and training track in surgical oncology across Europe has been emphasized. ESSO provides several hands-on courses for skills training and face-to-face discussions. The core curriculum provides a framework for the overall theoretical requirements in surgical oncology. The UEMS/EBSQ fellowship exam is designed to test core
Kjetil Søreide +4 more
openaire +6 more sources
Interethnic differences in pancreatic cancer incidence and risk factors: The Multiethnic Cohort. [PDF]
, 2019 While disparity in pancreatic cancer incidence between blacks and whites has been observed, few studies have examined disparity in other ethnic minorities. We evaluated variations in pancreatic cancer incidence and assessed the extent to which known risk
Haiman, Christopher A +8 more
core +1 more source
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
New England Journal of Medicine, 2018 BACKGROUND Among patients with metastatic pancreatic cancer, combination chemotherapy with fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) leads to longer overall survival than gemcitabine therapy.
T. Conroy +31 more
semanticscholar +1 more source
The Lancet, 2011 Substantial progress has been made in our understanding of the biology of pancreatic cancer, and advances in patients' management have also taken place. Evidence is beginning to show that screening first-degree relatives of individuals with several family members affected by pancreatic cancer can identify non-invasive precursors of this malignant ...
Audrey, Vincent +4 more
openaire +2 more sources
Surgical Case Reports, 2018 Background Surgeons sometimes must plan pancreatoduodenectomy (PD) for patients with a variant common hepatic artery (CHA) branching from the superior mesenteric artery (SMA) penetrating the pancreatic parenchyma, known as a transpancreatic CHA (tp-CHA).
Takashi Miyata +12 more
doaj +1 more source
Cancer Cell International, 2021 Background High tumor mutation burden (TMB) has gradually become a sensitive biomarker for predicting the response to immunotherapy in many cancers, including lung, bladder and head and neck cancers.
Rong Tang +10 more
doaj +1 more source
A novel protein isoform of the RON tyrosine kinase receptor transforms human pancreatic duct epithelial cells. [PDF]
, 2016 The MST1R gene is overexpressed in pancreatic cancer producing elevated levels of the RON tyrosine kinase receptor protein. While mutations in MST1R are rare, alternative splice variants have been previously reported in epithelial cancers.
Babicky, M +10 more
core +2 more sources
Pancreatic cancer cachexia: a review of mechanisms and therapeutics. [PDF]
, 2014 Over the last decade, we have gained new insight into the pathophysiology of cachexia associated with pancreatic cancer. Unfortunately, its treatment is complex and remains a challenge.
Andrew Eugene Hendifar +8 more
core +2 more sources
KRAS mutation in pancreatic cancer.
Seminars in Oncology, 2021 Pancreatic cancer is a recalcitrant cancer with one of the lowest 5-year survival rates. A hallmark of pancreatic cancer is the prevalence of oncogenic mutation in the KRAS gene.
Ji Luo
semanticscholar +1 more source
Epigallocatechin-3-Gallate (EGCG) Suppresses Pancreatic Cancer Cell Growth, Invasion, and Migration partly through the Inhibition of Akt Pathway and Epithelial-Mesenchymal Transition: Enhanced Efficacy when Combined with Gemcitabine. [PDF]
, 2019 Most pancreatic cancers are usually diagnosed at an advanced stage when they have already metastasized. Epigallocatechin-3-gallate (EGCG), a major polyphenolic constituent of green tea, has been shown to reduce pancreatic cancer growth, but its effect on
Hackman, Robert M +4 more
core +2 more sources